Herbal Tea Trial Adds a Systemic Arm to Refractory Interstitial Cystitis Care
A randomized trial in Taiwan is testing whether Jing Si Herbal Tea can improve outcomes in people with refractory interstitial cystitis/bladder pain syndrome when added to bladder-directed therapy. The study is being conducted at Hualien Tzu Chi General Hospital and is designed for patients whose symptoms have persisted despite cystoscopic hydrodistention, antimuscarinic therapy, and pain medication.
The clinical target is a difficult one. IC/BPS can drive persistent pain, urinary frequency, urgency, and nocturia even after standard interventions, and the record’s rationale links those symptoms to chronic bladder wall inflammation and mucosal denudation. In that framework, a therapy that may modulate autonomic tone, immune activity, and oxidative stress is being positioned as an adjunct rather than a replacement for intravesical treatment.
This is not a soft endpoint study. Investigators plan to ask a specific question: does adding the herbal liquid packet to ongoing urological therapy improve the patient’s global impression of change enough to justify its use in a population that has already failed several conventional strategies?
Why the Trial Focuses on a Resistant IC/BPS Population
Eligibility is narrow by design. Participants must have non-ulcer IC/BPS features, glomerulation greater than 1, and an Interstitial Cystitis Symptom Index score of at least 12 after prior treatment has failed to produce meaningful improvement. The study excludes Hunner-type disease, bladder outlet obstruction, significant post-void residual urine, active urinary tract infection, severe cardiopulmonary disease, and pregnancy, among other conditions.
That selection matters because refractory IC/BPS is a heterogeneous syndrome. Patients who continue to have bladder pain and urgency after standard care may have ongoing inflammatory signaling, impaired urothelial integrity, or altered sensory processing that does not respond well to a single therapy. A combined strategy may be more plausible in this setting than in newly diagnosed disease, where symptom trajectories can be less stable and more variable.
The intervention is layered onto one of several bladder-focused treatments already planned for the patient: intravesical hyaluronic acid, botulinum toxin A, platelet-rich plasma, or low-energy shock wave therapy. Investigators are therefore testing a broad supportive approach, not a standalone bladder cure.
Endpoints Centered on Symptom Relief and Patient Experience
The primary endpoint is improvement in global response assessment by 2 points at 12 weeks. That is a practical choice for a disorder in which symptom burden, not laboratory normalization, drives clinical urgency. Patient-reported outcomes dominate the study design, and for good reason: IC/BPS is often defined by how much the condition disrupts daily life rather than by a single biomarker or imaging finding.
Several familiar measures will be tracked at baseline and again after treatment, including the voiding diary, ICSI, IC problem index, pain ratings, patient perception of bladder condition, GRA, maximal flow rate, voided volume, and post-void residual urine. Urine samples will also be collected for biomarker testing before and after therapy.
A single sentence captures the clinical pressure point here: pain relief may be the most visible bedside signal of benefit.
The protocol also expects urinary biomarker changes to parallel symptom improvement. That expectation aligns with the biological model presented in the record, where bladder inflammation and mucosal injury are treated as central drivers of urgency, frequency, and pain. If urinary inflammatory markers fall alongside symptom scores, the trial could support the idea that the herbal packet is influencing the underlying inflammatory milieu rather than merely altering perception of discomfort.
Combined Therapy May Be the Real Test
The control arm receives intravesical IC therapy plus placebo, while the treatment arm receives the same bladder-directed approach together with Jing Si Herbal Tea liquid packet three times daily for 3 months. Because both groups receive active urological care, any separation between arms would suggest an incremental effect from the oral intervention, not just improvement from ongoing procedural treatment.
The timing of assessments is also important. Follow-up at 4, 12, and 20 weeks should help determine whether any early symptom changes persist or whether the effect fades once the combined regimen ends. In IC/BPS, transient improvement can be misleading. Durable change is what would matter at the bedside, particularly for patients who have already cycled through several unsuccessful therapies.
Investigators also anticipate that the pain score may prove to be the most sensitive indicator of outcome. That expectation is biologically sensible. Pain in IC/BPS often reflects persistent urothelial injury, inflammatory signaling, and visceral hypersensitivity; if a treatment eases that burden, pain may shift before more complex urinary metrics do.
Safety Boundaries and the Limits of the Current Design
The protocol excludes patients with severe renal or hepatic laboratory abnormalities, uncontrolled infection, significant bladder emptying problems, or inability to complete a voiding diary. Those restrictions reduce the chance that confounding medical illness will obscure interpretation of the results, but they also narrow the population to a relatively stable outpatient cohort.
Enrollment is estimated at 80 participants, which is modest for a disorder with variable symptom expression and multiple possible procedural backdrops. The study is randomized, parallel, and double masked, yet the record provided does not supply results, so any effect remains hypothetical until the trial readout appears.
The most clinically relevant question is whether a traditional Chinese medicine product can add measurable value on top of intravesical IC treatment in patients already difficult to treat. If the GRA signal improves and pain scores fall in parallel, the result would support a combined approach grounded in symptom relief and inflammatory modulation. If not, the study will still define the boundaries of what this adjunct can do in a refractory bladder pain population.